Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
Background. Cytarabine use during pregnancy carries a 5-7% risk of neonatal cytopenia. We report two cases of fetal myelosuppression following high-dose cytarabine administration for acute myeloid leukemia (AML). Case 1. A 36-year-old G9P6 diagnosed with AML at 21 weeks was monitored for fetal anemi...
Saved in:
Main Authors: | Jessica Parrott (Author), Marium Holland (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucose Metabolism as a Potential Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia
by: Joana Pereira-Vieira, et al.
Published: (2024) -
Standard dose Cytarabine-Induced Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Report
by: Mehrshad Ebrahimpour, et al.
Published: (2024) -
High-dose cytarabine associated hemorrhagic pericardial effusion in a child with acute myeloid leukemia
by: Swati Kapoor, et al.
Published: (2020) -
Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
by: Tomislav Smoljo, et al.
Published: (2023) -
Enhanced Antitumor Efficacy of Cytarabine and Idarubicin in Acute Myeloid Leukemia Using Liposomal Formulation: In Vitro and In Vivo Studies
by: Chunxia Zhu, et al.
Published: (2024)